Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

In 12 days, on October 28, Biogen Inc. will publish its results for the third quarter. As a reminder, in late July, the company raised its FY 2026 non-GAAP diluted EPS underlying guidance from $15.25-$16.25 to $15.85-$16.85. In Q2, Biogen's Alzheimer's collaboration revenue rose 16% YoY to $63.7 million.

Seeking Alpha • Oct 16, 2026

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Seeking Alpha • Oct 7, 2026

Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.

Proactive Investors • Oct 6, 2026

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 6, 2026

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

CNBC Television • Oct 6, 2026

25 Stocks to Avoid as October Trading Gets Underway

We are only two days into October, and there is already no shortage of volatility. Another surge in Treasury yields and crude prices saw stocks plummet Thursday, but by Friday, a cooldown in both alongside weaker-than-expected nonfarm payrolls data for September is boosting sentiment. As investors begin to look toward this month's upcoming Federal Open Market Committee (FOMC) meeting and more inflation and jobs data, join us in taking a look at 25 stocks you should not bet on during this season of uncertainty.

Schaeffers Research • Oct 6, 2026

Biogen's experimental lupus drug shows benefit against skin symptoms

Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of ​autoimmune disease in a mid-stage study.

Reuters • Oct 2, 2026

Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.

GlobeNewsWire • Oct 2, 2026

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Zacks Investment Research • Sep 28, 2026

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Zacks Investment Research • Sep 21, 2026